Pipeline

https://static.wixstatic.com/media/0f8e1f_042a41e5c3cb46979f87c7d69f5af122~mv2.png Number of Lead Molecules • 2 recombinant human Interferon-beta variants https://static.wixstatic.com/media/0f8e1f_50f76e6ad4cd4fab8c029a209ebfb089~mv2.png Therapeutic area • Autoimmune Disease Disease • Multiple Sclerosis (https://0f8e1f4b-60f0-490e-98db-47800f231180.usrfiles.com/ugd/0f8e1f_d9bee3b421fd4cdc988f5105e2d0e8ef.pdf) Clinical Need • Reduced immunogenicity Current SOC/Market: • Rebif®* (Interferon beta-1a); Merck KGaA • Immunosuppressant • ~$4B IFN-β market Supporting Data: • Precision glycosylated biobetters • Lower EC50 • Designed for reduced immunogenicity Status: _________________________________________________________________________ https://static.wixstatic.com/media/0f8e1f_69c587109a494bc885b24400ca4d5a4a~mv2.png Number of Lead Molecules • >500 recombinant human Interferon-beta variants Therapeutic area • Autoimmune Disease Disease • Multiple Sclerosis (https://0f8e1f4b-60f0-490e-98db-47800f231180.usrfiles.com/ugd/0f8e1f_d26eebd4827e468492114fd21580a8dd.pdf) Clinical Need • Reduced immunogenicity Current SOC/Market: • Rebif®* (Interferon beta-1a); Merck KGaA • Immunosuppressant • ~$4B IFN-β market Supporting Data: • Comparable EC50 to reference drug Status: _________________________________________________________________________ https://static.wixstatic.com/media/0f8e1f_3ffa498709de4748a556ea75a4c0ee96~mv2.png Number of Lead Molecules • 1 Interferon hybrid Therapeutic area • Autoimmune Disease Disease • Multiple Sclerosis Clinical Need • Reduced immunogenicity Current SOC/Market: • Rebif®* (Interferon beta-1a); Merck KGaA • Immunosuppressant • ~$4B IFN-β market Supporting Data: • Hybrid molecule of two genes • Increased potency Status: _________________________________________________________________________ https://static.wixstatic.com/media/0f8e1f_dd36ad944d8b4882b932d10735b470bf~mv2.png Number of Lead Molecules • >350 recombinant human Interferon-α2 variants https://static.wixstatic.com/media/0f8e1f_b5d5235153944926829cbe55b4125f3d~mv2.png Therapeutic area • Cancer, Immunology Disease • Acute Myeloid Leukemia,(https://0f8e1f4b-60f0-490e-98db-47800f231180.usrfiles.com/ugd/0f8e1f_46034c78b6cb48ccadc2544e7c79e37d.pdf) Squamous Cell Carcinoma, Polycythemia Vera, Hepatitis D (https://0f8e1f4b-60f0-490e-98db-47800f231180.usrfiles.com/ugd/0f8e1f_0dc4c2a73ef2423fbf6ec0edddfb6ab3.pdf) Clinical Need • Susceptible to relapse Current SOC/Market • Pegasys®* (peginterferon alfa-2); Genentech • Blocks relapse • ~$2B AML market Supporting Data • Precision post-translational modifications • Precision guided disulfide bonds • Various modifications for improved potency Status: _________________________________________________________________________ https://static.wixstatic.com/media/0f8e1f_1aa5779fe597461c8a20a8b71ce68946~mv2.png Number of Lead Molecules • >1600 recombinant human Interferon-α2 variants Therapeutic area • Cancer, Immunology Disease • Acute Myeloid Leukemia, Squamous Cell Carcinoma, Polycythemia Vera, Viral Infection Clinical Need • Susceptible to relapse Current SOC/Market • Pegasys®* (peginterferon alfa-2); Genentech • Blocks relapse • ~$2B AML market Supporting Data • Precision post-translational modifications • Precision guided disulfide bonds • Various modifications for improved potency Status: _________________________________________________________________________ https://static.wixstatic.com/media/0f8e1f_0b2e745c984d401699927f3f766de56e~mv2.png Number of Lead Molecules • 16 recombinant human interferon chimeras Therapeutic area • Cancer, Immunology Disease • Acute Myeloid Leukemia, Squamous Cell Carcinoma, Polycythemia Vera, Viral Infection Clinical Need • Limited efficacy Current SOC/Market • Pegasys®* (peginterferon alfa-2); Genentech • Immune modulator • ~$3B IFN-alpha2 market Supporting Data • Dual gene agonist • Improved activity compared to IFN-alpha2 Status: _________________________________________________________________________ *Manufactured drugs are registered trademarks of third parties.

https://static.wixstatic.com/media/0f8e1f_9cf60bde296646cea49b60ba2fabb003~mv2.png Number of Lead Molecules • TBD; variant libraries are currently being designed to thousands of unique GLP-1 variants with our powerful cell-based GigaAssay platform—engineered to discover leads with superior potency, enhanced stability, and lower immunogenicity compared to current reference products. Therapeutic area • Metabolic disorder Disease • Obesity (https://0f8e1f4b-60f0-490e-98db-47800f231180.usrfiles.com/ugd/0f8e1f_55ac0351205d498388e2815646608710.pdf) Clinical Need • Limited potency • Immunogenic • GI-related side effects Current SOC/Market: • Semaglutide® * (GLP-1) (Novo Nordisk) • Improved glycemic control, weight management • ~$60B GLP-1 market Supporting Data: • TBD Status: _________________________________________________________________________ https://static.wixstatic.com/media/0f8e1f_00d389b685ee41dd9f2cddc2643662aa~mv2.png Number of Lead Molecules • TBD; variant libraries are currently being designed to thousands of unique GLP-1 variants with our powerful cell-based GigaAssay platform—engineered to discover leads with similar potency, enhanced stability, and lower immunogenicity compared to current reference products. Therapeutic area • Metabolic disorder Disease • Obesity (https://0f8e1f4b-60f0-490e-98db-47800f231180.usrfiles.com/ugd/0f8e1f_cf6ff0d14a6a44f8a03f25eae7741c20.pdf) Clinical Need • Limited potency • Immunogenic • GI-related side effects Current SOC/Market: • Semaglutide® * (GLP-1) (Novo Nordisk) • Improved glycemic control, weight management • ~$60B GLP-1 market Supporting Data: • TBD Status: _________________________________________________________________________ https://static.wixstatic.com/media/0f8e1f_ca567cfbee3c406a8b60f3cadfafa8c4~mv2.png Number of Lead Molecules • TBD; variant libraries are currently being designed to unlock thousands of proprietary Incretin (GLP-1, GIP, GCG) variants, rapidly designed and tested in our high-throughput cell-based GigaAssay. We will discover optimized, balanced leads with superior potency across GLP1R, GIPR, and GCGR—delivering enhanced stability and reduced immunogenicity beyond current reference products. Therapeutic area • Metabolic disorder Disease • Obesity (https://0f8e1f4b-60f0-490e-98db-47800f231180.usrfiles.com/ugd/0f8e1f_9c98316ecb69453d93257fb5d6a3119b.pdf) Clinical Need • Limited potency • Immunogenic • GI-related side effects Current SOC/Market: • Retatrutide® * (Incretin tri-agonist) (Eli Lilly & Company) • Improved glycemic control, weight management • ~$60B GLP-1 market Supporting Data: • TBD Status: _________________________________________________________________________ *Manufactured drugs are registered trademarks of third parties.

https://static.wixstatic.com/media/0f8e1f_57cfddacfad7476185f3250fb4dc5aca~mv2.png Number of Drug Resistant Variants • >100 Therapeutic area • Cancer Disease • HER2+ breast cancer Clinical Need • Therapies rotated without biomarker-driven guidance Current SOC/Market • HER2+ companion diagnostic Key points about the significance of HER2 • HER2 (human epidermal growth factor receptor 2) is a protein and gene that plays a critical role in cell growth and division. Its significance is most prominent in breast cancer, where about 20-30% of tumors display HER2 gene amplification or protein overexpression, leading to a subtype known as HER2-positive breast cancer. • Driver of Aggressive Cancer: When the HER2 gene is amplified, it causes excessive production of the HER2 protein, which in turn triggers uncontrolled cell growth. This results in a particularly aggressive subtype of breast cancer with a tendency for rapid growth and higher risk of recurrence. • Therapeutic Target: The identification of HER2 as a driver of cancer led to the development of targeted therapies, such as trastuzumab (Herceptin), which have dramatically improved the prognosis for patients with HER2-positive tumors. Effective treatment is closely linked to precise determination of HER2 status. • Clinical Decision-Making: HER2 status is now routinely tested in breast cancer diagnoses. It guides treatment decisions: tumors positive for HER2 typically benefit from anti-HER2 therapies, while those that are HER2-negative do not. • Prognosis and Predictive Value: HER2 positivity is associated with greater tumor aggressiveness and used to predict how a patient will respond to specific treatments, including certain chemotherapies and hormonal therapies. • Molecular Function: HER2 is one of four related receptors (HER1-4) on the cell surface that, when activated (usually by dimerization), trigger intracellular signaling cascades involved in proliferation and survival. Unlike other family members, HER2 does not require a ligand and acts mainly through partnering with other HER family proteins. Supporting Data • Expanded HER2 resistance map: 6,000 variants tested -> 250+ resistance mutations identified (vs. 3 known) across 3 key drugs. Status: __________________________________________________________________